骨质疏松相关分子病因及治疗研究进展  

Research progress on molecular etiology and treatment of osteoporosis

作　　者：邓飞飞 宋强 张成涛 尹若峰[1] Deng Feifei;Song Qiang;Zhang Chengtao;Yin Ruofeng(Department of Orthopedics,the China-Japan Union Hospital of Jilin University,Changchun 130033,China)

机构地区：[1]吉林大学中日联谊医院骨科,长春130033

出　　处：《中华实验外科杂志》2021年第6期1186-1188,共3页Chinese Journal of Experimental Surgery

摘　　要：骨质疏松是一种以骨骼强度下降、骨微结构退变、骨骼脆性增加的全身性骨骼疾病,严重威胁着中老年患者身心健康。随着骨质疏松症的发病原因相关研究不断深入,更多研究转向骨质疏松相关分子发病机制及针对性治疗药物研究。本文重探讨骨质疏松的相关分子发病机制及目前临床相关治疗方式,为目前骨质疏松症的临床致病机制分子研究及治疗上作一综述。Osteoporosis is a systemic bone disease with decreased bone strength and increased bone fragility,which seriously threatens the physical and mental health of middle-aged and elderly patients.With the continuous in-depth research on the causes of osteoporosis,more research has begun to turn to the molecular pathogenesis of osteoporosis and targeted treatment drugs.This article focuses on the molecular pathogenesis of osteoporosis and current clinical related treatment methods,aiming to summarize the molecular research and treatment of the current clinical pathogenesis of osteoporosis,and lay a certain foundation for subsequent research.

关 键 词：骨质疏松 病因 发病机制 治疗 

分 类 号：R580[医药卫生—内分泌]